Johnson & Johnson Announces Expansion of Imbruvica (ibrutinib) Label in the U.S. to Include Oral Suspension Formulation for Adult Patients in its Approved Indications

HORSHAM, PA. February 26, 2024– Johnson& Johnson, in collaboration with its alliance partner, Pharmacyclics LLC, an AbbVie Company, announced today that the U.S. Food and Drug Administration (FDA) has approved a label expansion for...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news